Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2181 · · 10 pages · English
Summary by 6ix AI
It confirms the total authorised share capital and provides details on issued shares and public float sufficiency. The report indicates that there were no changes in the number of issued shares or treasury shares during the month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Mabpharm
- 2026 Interim Report
- Third Amended and Restated memorandum and articles of association
- Voluntary announcement approval from the national medical products administration on the new drug application (nda) of our pipeline product, CMAB807X (denosumab injection)
Follow Mabpharm into a list and get an email when it puts out news.
Follow Mabpharm